Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

Background: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose of ARPIs. This study compared the prognosis in pa...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2022-03-01
Schriftenreihe:	Prostate International
Schlagworte:	Abiraterone Androgen receptor pathway inhibitor Castration-resistant prostate cancer Dose reduction Enzalutamide
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2287888221000556
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!